Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 23532247)

1.

Macrolides and bronchiectasis: clinical benefit with a resistance price.

Elborn JS, Tunney MM.

JAMA. 2013 Mar 27;309(12):1295-6. doi: 10.1001/jama.2013.2780. No abstract available.

PMID:
23532247
2.

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG.

JAMA. 2013 Mar 27;309(12):1251-9. doi: 10.1001/jama.2013.1937.

PMID:
23532241
3.

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD.

JAMA. 2013 Mar 27;309(12):1260-7. doi: 10.1001/jama.2013.2290.

PMID:
23532242
5.

[New therapeutic uses of the macrolides].

Mihălţan F.

Pneumologia. 2004 Jul-Sep;53(3):100-4. Review. Romanian. No abstract available.

PMID:
16108157
6.

The newer macrolides. Azithromycin and clarithromycin.

Zuckerman JM, Kaye KM.

Infect Dis Clin North Am. 1995 Sep;9(3):731-45. Review.

PMID:
7490441
8.

Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations.

Serisier DJ, Martin ML.

Respir Med. 2011 Jun;105(6):946-9. doi: 10.1016/j.rmed.2011.01.009. Epub 2011 Mar 1.

9.

Role of long term antibiotics in chronic respiratory diseases.

Suresh Babu K, Kastelik J, Morjaria JB.

Respir Med. 2013 Jun;107(6):800-15. doi: 10.1016/j.rmed.2013.02.009. Epub 2013 Mar 20. Review.

PMID:
23522403
10.

[Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community].

Guchev IA, Klochkov OI, Ivanitsa GV, Pervov IuA, Shturmina SM, Rosman SV.

Antibiot Khimioter. 2004;49(8-9):34-5, 37-42. Russian.

PMID:
15727144
11.

[Application progress of macrolide sustained therapy for bronchiectasis].

Fan L, Xu J.

Zhonghua Jie He He Hu Xi Za Zhi. 2014 Jan;37(1):48-50. Review. Chinese. No abstract available.

PMID:
24694975
12.

The macrolides: erythromycin, clarithromycin, and azithromycin.

Alvarez-Elcoro S, Enzler MJ.

Mayo Clin Proc. 1999 Jun;74(6):613-34. Review.

PMID:
10377939
13.

The newer macrolides: azithromycin and clarithromycin.

Zuckerman JM.

Infect Dis Clin North Am. 2000 Jun;14(2):449-62, x. Review.

PMID:
10829265
14.

Macrolide antibiotic therapy in patients with cystic fibrosis.

Schöni MH.

Swiss Med Wkly. 2003 May 31;133(21-22):297-301. Review.

15.

Azithromycin chemoprophylaxis.

Gray GC, Ryan MA.

J Infect Dis. 2001 Sep 1;184(5):657. No abstract available.

16.

Bronchiectasis: breaking the cycle of inflammation and infection.

Mandal P, Hill AT.

Lancet Respir Med. 2013 Mar;1(1):e5-6. doi: 10.1016/S2213-2600(13)70005-5. Epub 2013 Jan 14. No abstract available.

PMID:
24321816
17.

All generalizations are false including this one.

Singh N.

Respirology. 2007 Jul;12(4):623-4; author reply 625. No abstract available.

PMID:
17587437
18.

[Azithromycin (sumamed)--in the treatment of respiratory tract infections].

Fomina IP, Smirnova LB, Iudin SM.

Antibiot Khimioter. 1996 Feb;41(2):52-61. Review. Russian. No abstract available.

PMID:
8929121
19.

Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin?

Kirk CB.

Arch Dis Child. 2008 May;93(5):442-4. Epub 2007 Oct 1. Review. No abstract available.

PMID:
17908711
20.

Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens.

Cizman M, Pokorn M, Seme K, Paragi M, Orazem A.

Eur J Clin Microbiol Infect Dis. 1999 Jul;18(7):522-4.

PMID:
10482034
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk